ROCHE HLDG - Dusseldorf Stock Exchang (RHO DU) stock market data APIs
€351.1205
-0.51(-0.1%)
as of December 18, 2025
Try our APIs with
free plan!
ROCHE HLDG - Dusseldorf Stock Exchang Financial Data Overview
Price chart is built with
Anychart
There is no Profile data available for RHO.DU.
Prev. Close
351.1205
Open
350.6128
High
351.5782
Low
348.8089
52 wk Range
235.2567-355.4
Market Cap
312 681 M
Dividends (Yield)
0.0415
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get ROCHE HLDG - Dusseldorf Stock Exchang data using free add-ons & libraries
Get ROCHE HLDG - Dusseldorf Stock Exchang Fundamental Data
ROCHE HLDG - Dusseldorf Stock Exchang Fundamental data includes:
- Net Revenue:
- EBITDA:
- Earnings Per Share: 0
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: NaN
- EPS/Forecast: NaN
Get ROCHE HLDG - Dusseldorf Stock Exchang End-of-day data
EOD Historical Data package for
$
19.99
/mo.
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
ROCHE HLDG - Dusseldorf Stock Exchang News
New
PCSA Stock Soars on Upbeat Clinical Update From Breast Cancer Study
Shares of Processa Pharmaceuticals PCSA surged 122.3% on Wednesday after the company provided an encouraging clinical update on its ongoing mid-stage study evaluating its investigational candidate NG...
Ulcerative Colitis Market Poised for Strong Expansion During the Forecast Period (2025-2034) Driven by Biologic and Novel Therapy Adoption Landscape | DelveInsight
The ulcerative colitis market is experiencing steady growth driven by rising disease prevalence and increasing diagnosis rates worldwide. Expanding adoption of advanced biologics, small-molecule thera...
Health Canada authorizes TNKase® (tenecteplase) for the treatment of Acute Ischemic Stroke (AIS)
The approval marks the first new stroke treatment authorized in nearly 27 years, offering an additional option for managing acute ischemic stroke in Canada. MISSISSAUGA, ON, Dec. 17, 2025 /CNW/ - Ho...
AZN, Daiichi's Enhertu Gets FDA Nod for First-Line Breast Cancer
AstraZeneca PLC AZN and its Japan-based partner Daiichi Sankyo announced that the FDA has approved their blockbuster antibody-drug conjugate (ADC), Enhertu, for first-line use in breast cancer. Enhert...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
